New: Instantly spot drawdowns, dips, insider moves, and breakout themes across Maps and Screener.

Learn More

DaVita HealthCare (DVA) Stock Falls Amid Market Uptick: What Investors Need to Know

By Zacks Equity Research | January 27, 2026, 6:00 PM

DaVita HealthCare (DVA) ended the recent trading session at $105.61, demonstrating a -1.77% change from the preceding day's closing price. This change lagged the S&P 500's 0.41% gain on the day. Meanwhile, the Dow experienced a drop of 0.83%, and the technology-dominated Nasdaq saw an increase of 0.91%.

Prior to today's trading, shares of the kidney dialysis provider had lost 5.28% lagged the Medical sector's loss of 0.74% and the S&P 500's gain of 0.38%.

The investment community will be closely monitoring the performance of DaVita HealthCare in its forthcoming earnings report. The company is scheduled to release its earnings on February 2, 2026. The company's earnings per share (EPS) are projected to be $3.24, reflecting a 44.64% increase from the same quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $3.53 billion, up 6.99% from the year-ago period.

For the full year, the Zacks Consensus Estimates project earnings of $10.7 per share and a revenue of $13.55 billion, demonstrating changes of +10.54% and 0%, respectively, from the preceding year.

Investors might also notice recent changes to analyst estimates for DaVita HealthCare. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. DaVita HealthCare currently has a Zacks Rank of #3 (Hold).

Digging into valuation, DaVita HealthCare currently has a Forward P/E ratio of 8.34. This expresses a discount compared to the average Forward P/E of 18.62 of its industry.

It is also worth noting that DVA currently has a PEG ratio of 0.66. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As the market closed yesterday, the Medical - Outpatient and Home Healthcare industry was having an average PEG ratio of 1.87.

The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 174, positioning it in the bottom 29% of all 250+ industries.

The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
DaVita Inc. (DVA): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Mentioned In This Article

Latest News